Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Citius Pharmaceuticals Inc

CTXR ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$0.76

▲ +3.00%

Market Cap $20.74M · Vol 47.25K

Key Metrics

P/E Ratio

N/A

FWD: 0.32

Market Cap

$20.74M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

65.89

Momentum

Beta

1.08

vs Market

52W High

$2.18

65.34% below

52W Low

$0.47

60.83% above

Volume

47.25K

Avg 50.45K

P/B

0.33

Price-to-book

ROE

N/A

Return on equity

Free Float

98.20%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Citius Pharmaceuticals Inc (CTXR) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CTXR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+10.74%

+42.03%

+4.94%

-1.25%

YTD

-2.75%

-42.32%

-96.49%

-98.33%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-39,740,270.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-31.25% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	0.32
PEG Ratio	N/A
P/S	N/A
P/B	0.33
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	27.45M

Technical Indicators

50-Day SMA	$0.58
200-Day SMA	$0.81
RSI (14)	65.89
Beta	1.08
52-Week High	$2.18
52-Week Low	$0.47

Volume Today	47.25K
Avg Daily Volume (30D)	50.45K
Relative Volume	0.94x
Volatility (10D)	157.76
Volatility (30D)	123.89
Free Float	98.20%

Analyst Consensus

N/A

Current Price $0.76

Mean Target N/A

52W Low$0.47 52W High$2.18

Current

Target

$0.47 $2.18

Current Analyst target

· 0 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001V1J7S4

ISINUS17322U3068

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.